Patents Assigned to Pfizer
  • N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
    Patent number: 6660756
    Abstract: The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2 R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: December 9, 2003
    Assignee: Pfizer Inc.
    Inventors: Stephen Challenger, Andrew Simon Cook, Adam Thomas Gillmore, Donald Stuart Middleton, David Cameron Pryde, Alan Stobie
  • Method for enhanced NMR chemical structure determination
    Publication number: 20030224533
    Abstract: A method for enhancing the NMR spectroscopy structural analysis of compounds and particularly the structural analysis of compounds used in developing viable drugs, by increasing signal to noise (S/N) ratio of obtained spectra by collecting and storing NMR in a standard data matrix and generating a point by point weighting function for each dimension of the matrix.
    Type: Application
    Filed: October 15, 2002
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventor: Walter Massefski
  • Immediate release dosage forms containing solid drug dispersions
    Publication number: 20030224043
    Abstract: High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility.
    Type: Application
    Filed: January 31, 2003
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Leah E. Appel, John E. Byers, Marshall D. Crew, Dwayne T. Friesen, Bruno C. Hancock, Stephen J. Schadtle
  • Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Publication number: 20030225056
    Abstract: The present invention relates to triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: April 25, 2003
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Kevin D. Freeman-Cook, Mark C. Noe
  • Rapid assay to assess the potential for glucocorticoid analogs to promote the differentiation of human osteoblasts and predict bone safety
    Publication number: 20030224349
    Abstract: This invention relates to in vitro screening and assay methods for the selection of anti-inflammatory compounds that exhibit minimized effects on the differentiation of human osteoblasts.
    Type: Application
    Filed: June 2, 2003
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventor: Leonard Buckbinder
  • 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Patent number: 6656945
    Abstract: 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc
    Inventors: Simon Fraser Campbell, Alexander Roderick MacKenzie, Anthony Wood
  • Attenuated live neospora vaccine
    Patent number: 6656479
    Abstract: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc.
    Inventors: David A Brake, Byron L Blagburn, David S Lindsay
  • Methods of making quinoline amides
    Patent number: 6657065
    Abstract: The present invention relates to methods of making quinoline amides of Formula I below, which are microsomal triglyceride transfer protein inhibitors and can be used as medicines. The present invention also relates to compounds that are used to make quinoline amides of Formula I and methods of making these compounds.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc
    Inventors: Norma J. Tom, David C. Whritenour
  • Combinations of &bgr;3 agonists and growth hormone secretagogues
    Patent number: 6657063
    Abstract: This invention is directed to pharmaceutical compositions comprising &bgr;3 adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc.
    Inventor: Robert L. Dow
  • Solid pharmaceutical dispersions with enhanced bioavailability
    Publication number: 20030219489
    Abstract: Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.
    Type: Application
    Filed: June 9, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: William J. Curatolo, Scott M. Herbig, James A. S. Nightingale
  • Assay for activity of the ActRIIB kinase
    Publication number: 20030219846
    Abstract: The present invention relates to kinase assays, and specifically to novel kinase assay methods using a novel target peptide for measuring the activity and/or modulation of activity of the ActRIIB kinase protein.
    Type: Application
    Filed: February 14, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Philip A. Krasney, Michael Norcia, Barbara A. O'Connor, Robin W. Spencer
  • Quinoline and quinazoline compounds useful in therapy
    Publication number: 20030220332
    Abstract: The invention provides compounds of formula (I), 1
    Type: Application
    Filed: June 4, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Alan John Collis, David Nathan Abraham Fox, Julie Newman
  • Pyrrolo[2,3-d]pyrimidine compounds
    Publication number: 20030220353
    Abstract: A compound of the formula 1
    Type: Application
    Filed: June 16, 2003
    Publication date: November 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof
  • Quinoline and quinazoline compounds useful in therapy
    Patent number: 6653302
    Abstract: Compounds of formula I, wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted; R4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent, or represents a cyclic group of formula Ia, or represents a chain of formula Ib, and pharmaceutically acceptable salts thereof; are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: November 25, 2003
    Assignee: Pfizer Inc.
    Inventor: David Nathan Abraham Fox
  • Method of treating irritable bowel syndrome
    Patent number: 6653339
    Abstract: The present invention is directed to a a method for the treatment of irritable bowel syndrome comprising the multiple daily pulse dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: November 25, 2003
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Michael John Humphrey, Paul Quinn
  • Use of PDE5 inhibitors in the treatment of scarring
    Publication number: 20030216407
    Abstract: This invention relates to the use of selective cyclic guanosine 3′,5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue.
    Type: Application
    Filed: January 24, 2003
    Publication date: November 20, 2003
    Applicant: Pfizer Inc.
    Inventors: Richard Philip Butt, Stephen Charles Phillips
  • Androgen receptor overexpressing skeletal myoblasts
    Publication number: 20030215888
    Abstract: This invention relates to mammalian skeletal myoblasts that overexpress the androgen receptor and screening methods for identifying and characterizing androgen receptor modulators.
    Type: Application
    Filed: February 27, 2003
    Publication date: November 20, 2003
    Applicant: Pfizer Inc.
    Inventors: Lydia C. Pan, Xiao-Ning Wang
  • Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor
    Publication number: 20030216294
    Abstract: The present invention provides methods of treating non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance, the methods comprising the step of administering to a patient having or at risk of having non-insulin dependent diabetes mellitus, insulin resistance, Syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataracts, hyperglycemia, or impaired glucose tolerance a synergistic amount of: 1) a sulfonylurea, a non-sulfonylurea K+ ATP channel blocker, or a sulfonylurea and a non-sulfonylurea K+ ATP channel blocker; and 2) a cAMP phosphodiesterase type 3 inhibitor.
    Type: Application
    Filed: June 5, 2003
    Publication date: November 20, 2003
    Applicant: Pfizer Inc.
    Inventors: David A. Fryburg, Janice C. Parker
  • Methods for preparing CETP inhibitors
    Publication number: 20030216576
    Abstract: This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors.
    Type: Application
    Filed: April 18, 2003
    Publication date: November 20, 2003
    Applicant: Pfizer Inc.
    Inventors: David B. Damon, Robert W. Dugger, Robert W. Scott
  • Prevention of loss and restoration of bone mass by certain prostaglandin agonists
    Patent number: 6649657
    Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: November 18, 2003
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson